EFSA rejects two new 13.5 claims on ‘transit’ and ‘vaginal moisture’

By Nathan Gray

- Last updated on GMT

The European Food Safety Authority (EFSA) has rejected two health claims dossiers for food supplements that claim to ‘improve transit’ and ‘reduction of vaginal dryness’.

The European regulatory authority’s panel on Dietetic Products, Nutrition and Allergies (NDA) the applications from French firm Vivatech and Swiss-based Nutrilinks.

Vivatech had applied to EFSA claiming that its Transitech food supplement “improves transit and durably regulates it,”​ while Nutrilinks had asked EFSA to provide a scientific opinion on a health claim related to its Femilub supplement for the maintenance of vaginal moisture. 

However EFSA's NDA panel rejected both claims, stating that Vivatech’s ‘Transitech’ had not been sufficiently characterised in the dossier, and that Nutrilinks had provided no human intervention studies for its food supplement ‘Femilub’.

“No human intervention studies were provided from which conclusions could be drawn for the scientific substantiation of the claim,”​ said EFSA. “A cause and effect relationship has not been established between the consumption of “Femilub” and maintenance of vaginal moisture.”

The Transitech supplement was said to contain “dried parts of Rheum palmatum L. and/or Rheum officinale Baillon and/or their hybrids standardised for hydroxyanthracene derivatives, of Althaea officinalis L., of Rosa centifolia L., ofOcimum basilicum L., of Coriandrum sativum L., dried juice of Cynara scolymus L. standardised for cynarine, Saccharomyces cerevisiae subsp. cerevisiae UVAFERM SC,Bifidobacterium longum R0175 and Lactobacillus helveticus R0052.”

In response to the application the NDA panel said it considered the information provided by Vivatech to be “insufficient to establish that Saccharomyces cerevisiae subsp. cerevisiaeUVAFERM SC was sufficiently characterised.”

“The Panel considers that if in a combination of several microorganisms and/or ingredients one microorganism or ingredient used in the combination is not sufficiently characterised, then the combination is considered to be not sufficiently characterised,”​ EFSA added.

Related news

Show more

Related products

show more

Unlock sensory innovation with AromatiQ™ technology

Unlock sensory innovation with AromatiQ™ technology

Content provided by Lonza | 20-Sep-2024 | Product Brochure

With 70% of consumers willing to pay a premium for a more enjoyable and memorable supplement experience, Lonza’s new AromatiQ™ technology enables brands...

From Biofarma a clinically tested vaginal protection

From Biofarma a clinically tested vaginal protection

Content provided by Biofarma Group | 05-Sep-2024 | Product Brochure

Bacterial vaginosis is considered the most common cause of vaginal infection among pregnant and non-pregnant women. In this scenario, the oral intake of...

Research to Reality: Restorative Sleep

Research to Reality: Restorative Sleep

Content provided by Gencor | 02-Sep-2024 | White Paper

Gencor prides itself on its cutting-edge, science-driven solutions. Explore sleep support through gold-standard, clinically-validated dietary supplement...

Ingredients to support women at every life stage

Ingredients to support women at every life stage

Content provided by Gencor | 21-Jun-2024 | White Paper

While addressing women’s health across all stages of life, we might as well have opened Pandora’s box. Dietary supplements can play an important role in...

Related suppliers

Follow us

Products

View more

Webinars